2014

DAY 1DAY 2DAY 3

Day 1 – Wednesday, 8 October 2014 

13:45 – 14:00 Chair : B. Boulanger, Arlenda, Belgium
Welcome –  Pre-Conference Workshop
14:00 – 15:30 J. Peterson, GSK, USA
Bayesian Applications to Quality-by-Design and Assay Development
Download slides
15:30 – 16:00 Coffee Break & Poster Session
16:00 – 17:30 J. Peterson, GSK, USA
Bayesian Applications to Quality-by-Design and Assay Development
Download slides
19:00 Drink at the Town Hall

Day 2 – Thursday, 9 October 2014

08:15 – 08:30 H. Geys, Janssen Pharma,  Belgium
Welcome – Main Conference
Session 1 Chair : O. Thas,  Ghent University, Belgium
Translational Research
08:30 – 09:15 W. Van Criekinge,  Ghent University, Belgium
Translational epigenomics 
Contributed papers
09:15 – 09:35 K. Gore, Pfizer, UK
Helping to Drive the Robustness of Preclinical Research
Download slides
09:35 – 09:55 R. Walley, UCB, UK
Demonstrating the impact of statistics in the preclinical area using Bayesian analysis with informative priors
Download slides
09:55 – 10:15 G. Chen, Merck, Netherlands
Bayesian tolerance interval
Download slides
 10:15 – 10:45 Coffee Break & Poster Session
Session 2 Chair : Pierre Lebrun, Arlenda, Belgium
Bioassays
10:45 – 11:30 C. Tan,  Pfizer, USA
A Step in the Right Direction? the development of USP Chapter <1210>
Download slides
Contributed papers
11:30 – 11:50 P. Sondag, B. Boulanger, E. Rozet, R. Rousseau, Arlenda, Belgium
Comparison of methodologies to assess the parallelism between two four parameters logistic curves
Download slides
11:50 – 12:10 J.-F. Michiels, T. Scherder, B. Boulanger, P. Lebrun, A. Jullion, Arlenda, Belgium
A Bayesian framework for conducting effective bridging between references under uncertainty
Download slides
12:10 – 12:30 A. Baclin, M-P. Malice, G. de Lannoy, M. Key Prato, GSK, Belgium
Control Chart to Monitor Quantitative Assay Consistency
Download slides
12:30 – 13:45 Lunch & Poster Session
Session 3 Chair : B. Boulanger, Arlenda, Belgium
Chemical Manufacturing & Control Bioassays
13:45 – 14:30 H. Yang, MedImmune, USA
Using statistical  innovation to impact regulatory thinking
Download slides
Contributed papers
14:30 – 14:50 P. C. Ijzerman-Boon, E. R. van den Heuvel, Merck, Netherlands
Validation of qualitative microbiological test methods
Download slides
14:50 – 15:10 E. Talens, Merck, Netherlands
Stability of reference standards
15:10 – 15:30 T. Mzolo, G. Goris, A. Di Bucchianico, E. van den Heuvel, University Medical Center Groningen, Netherlands
An Evaluation of Several Statistical Methods for Monitoring the Bioactivity of an In-house Reference Standard
15:30 – 15:50 A. Baclin, C. Bievelet, G. de Lannoy, M. Key-Prato,  M.-P. Malice, GSK, Belgium
A statistical method to demonstrate dilutional linearity for immunoassays
Download slides
15:50 – 16:20 Coffee Break & Poster Session
Session 4 Chair : Z. Shkedy, Hasselt University
QSTAR- an integrated analysis of biological, chemical and gene expression data in drug discovery
Download slides
16:20 – 17:05 H. Goehlmann, Janssen Pharma,  Belgium
ADA-Cutpoint estimation – using R: assumptions, solutions, problems
Contributed papers
17:05 – 17:25 F. Mattiello, O. Thas, Ghent University, Belgium
Two Explorative Data Analysis Methods for Discovering Connections Between Three Data Sources, with Applications in Early Drug Development
Download slides
17:25 – 17:45 N. J. Perualila, Hasselt University, Belgium
Rationalizing CMap Gene Expression Readouts via Target Prediction
Download slides
17:45 – 18:05 M. Otava, Hasselt University, Belgium
Regression with Enriched random forest
Download slides
20:00 Conference Dinner at brewery Halve Maan

Day 3 – Friday, 10 October 2014

 

12:40 – 14:00Lunch & Poster Session

Session 5 Chair : L. Bijnens, Janssen Pharma,  Belgium
Visualisation techniques 
08:30 – 09:00 D. Smeets, Icometrix, Leuven, Belgium
Volumetric images as a representation of clinical data 
09:00 – 09:30 R. Verbeeck, Janssen Pharma,  Belgium
The best of both worlds: guided analytics in the hands of the SME
Download slides
09:30- 10:00 T. Verbeke, OpenAnalytics, Belgium
Nonclinical Statistics Computing: The Big Picture
10:00 – 10:30 Coffee Break & Poster Session
Session 6 Chair : G. Verbeke,  iBiostat, Leuven University, Belgium
Omics
10:30 – 11:15 J. Goeman, Leiden University, Netherlands
Flexible multiple testing for drug screening
Download slides
Contributed papers
11:15 – 11:35 B. Verbist, K. Thys, J. Reumers, J. Aerssens, L. Bijnens, L. Clement, O. Thas, Janssen Pharma,  Belgium
Statistical methods for improved variant calling of massively parallel sequencing data within virology applications
Download slides
Session 7 Chair : L. A. Hothorn, Leibniz University Hannover 
Toxicology
11:35 – 12:20 J. Fox, USEPA-ORD-NCEA-W, USA
Test for Significant Toxicity: Time for Changes in the Analysis of Toxicity Test Data
Download slides
Contributed papers
12:20 – 12:40 L. A. Hothorn, Leibniz University Hannover
ADA-Cutpoint estimation – using R: assumptions, solutions, problems
Download slides
Session 8 Chair : T. Jacobs, Janssen Pharma,  Belgium
Pharmacology
14:00 – 14:45 T. Jaki,  Lancaster University, UK
Statistical approaches for Anti-Drug-Antibody (ADA) identification
Download slides
Contributed papers
14:45 – 15:05 J. Bright, AstraZeneca, UK
Reduce & Repeat – a way of obtaining more precise XC50s using fewer wells (in vitro) and fewer animals (in vivo)
Download slides
15:05 – 15:25 S. Janssen, J. Talpos, T. Jacobs, L. Fellini, T. Steckler, Janssen Pharma,  Belgium
Statistical Aspects for the Quantification of Learning Behaviour
Download slides
15:25 – 15:55 Coffee Break & Poster Session
15:55 – 16:15 E. Rozet, L. Natalis, B. Matthee, J. Swildens, T. Ritsema, W. Beumer, B. Boulanger, Arlenda, Belgium
Piecewise nonlinear mixed-effects model for modelling Nasal Potential Difference (NPD)
Download slides
16:15 – 16:35 L. Muchene, M. Otava, Z. Shkedy, T. Jacobs, Hasselt University, Belgium
Determination of the minimum effective dose for correlated dose-response data using Bayesian variable selection (BVS) models
Download slides
16:35 – 16:45 L. Bijnens, Janssen Pharma,  Belgium
Closing and Concluding Remark